世界各地的监管机构认识到人工智能在减少药物开发时间和成本方面的潜力，也开始建立支持将其整合到研究流程中的框架。这个市场有很多机会有待探索，特别是在医疗保健需求迅速增长的新兴经济体。公司可以利用人工智能来解决特定的本地健康挑战，并投资与学术机构建立合作伙伴关系，开展创新研究。此外，开放获取的生物医学数据集的日益普及，为人工智能系统提供了一个独特的机会，可以提高其在药物发现中的学习能力和准确性。
最近的趋势表明，制药公司越来越多地在其研究流程中采用机器学习算法和自然语言处理。这种转变正在增强目标识别并优化临床试验设计，从而带来更好的药物性能结果。人工智能技术公司和制药公司之间的合作计划日益普遍，显示出协同增长的趋势。随着技术进步推动全球药物发现和开发流程发生变革，市场对人工智能在药物发现领域的兴趣预计将日益增长。
来源：初步研究、二次研究、MRFR 数据库和分析师评论
美国国立卫生研究院等机构正在积极推动个性化医疗整合计划，并已投入超过10亿美元支持基因研发项目。这一趋势预计将加速人工智能在药物研发中的应用，因为人工智能算法可以分析海量数据集，确定适合个体患者的合适治疗靶点，从而推动市场增长。
这笔巨额资金投入凸显了人们对创新药物研发途径的日益关注，而人工智能正成为提高药物研发效率的关键技术。辉瑞和强生等大型制药公司正在采用人工智能方法来简化其开发流程，从而减少时间和成本并推动整个市场向前发展。
IBM 和 Google 等领先组织正在大力投资人工智能技术，创建复杂的算法，彻底改变药物研究的方式。这种变革性格局极大地增强了识别新型化合物和简化药物开发临床前和临床阶段的能力，推动了市场增长。
先导化合物优化紧随其后，2024 年的估值为 8.96 亿美元，预计在 2035 年将达到 50.16 亿美元；这一领域至关重要，因为它可以增强现有的候选药物，确保在进行临床试验之前提高疗效并减少副作用。药物再利用的市场价值在 2024 年将达到 9.78 亿美元，到 2035 年将增至 57.44 亿美元，这标志着一种战略方法，即对现有药物进行新治疗用途评估，从而减少传统药物开发通常涉及的时间和成本。
临床试验应用在 2024 年的价值为 14.67 亿美元，预计在 2035 年将达到 80.91 亿美元，在评估药物安全性和有效性方面发挥着至关重要的作用，而人工智能技术有助于更好地选择患者和设计试验，这在日益复杂的临床环境中至关重要。临床前测试的估值似乎较小，2024 年为 2.44 亿美元，预计到 2035 年将增长到 15.37 亿美元，这凸显了在人体试验前进行详尽测试以确保药物安全性和可行性的必要性。
来源：一手资料研究、二手资料研究、MRFR 数据库和分析师评论
深度学习对预测模型做出了重大贡献，从而可以实现更有针对性的治疗。知识图谱通过可视化不同数据集之间的连接来简化数据关系，从而提高药物发现的决策效率。最后，机器人流程自动化优化了重复性任务，使研究人员能够专注于创新。
研究机构利用人工智能来增强其在药物发现方面的研究能力，为创新和突破创造了巨大的机会。学术机构越来越多地将人工智能融入其教育课程，为下一代科学家提供未来行业发展所需的基本技能。
个性化医疗需求的不断增长以及加速药物开发的必要性，正在推动全球药物发现领域人工智能市场的扩张。技术进步和研发投入的不断增加显著促进了市场增长，凸显了每个终端用户在促进合作转变药物发现实践方面的关键作用。
预测模型有助于根据历史数据预测结果，这对于药物开发的明智决策至关重要。临床数据管理可确保临床试验数据的完整性和可访问性，从而促进更顺利的试验和监管审批。分析方法的开发仍然至关重要，因为它直接影响到识别治疗化合物的有效性和准确性。
亚太地区 2024 年的价值为 9.2 亿美元，预计将达到 53.2 亿美元，在医疗保健需求不断增长的背景下，亚太地区将成为人工智能技术投资的中心。南美、中东和非洲的市场份额较小，分别为 0.22 亿美元和 0.24 亿美元，但预计到 2035 年将扩大到 13 亿美元和 18.7 亿美元。尽管数字较小，但这些地区正在利用当地合作伙伴关系和投资激励措施来促进人工智能驱动的药物发现领域的增长。
来源：初步研究、二次研究、MRFR 数据库和分析师评论
诺华公司凭借其对创新和技术应用的承诺，在药物发现市场的人工智能领域脱颖而出。凭借强大的研发渠道，诺华公司已将人工智能融入其药物发现活动的各个方面，从而实现更高效的筛选和优化分子药物设计。与科技公司和学术机构的战略合作巩固了其市场地位，使诺华能够利用最先进的人工智能解决方案。
诺华的优势在于其涵盖各种治疗领域的广泛产品组合，以及其利用人工智能重新利用现有药物的能力，从而有可能加快药物发现过程。这种前瞻性的方法加上诺华已建立的行业声誉，巩固了其在利用人工智能技术进行药物发现全球应用方面的竞争优势。
Atomwise 是药物发现市场中人工智能的另一个关键参与者，因其在药物设计和开发中对人工智能的创新应用而闻名。该公司的专有技术利用深度学习算法来预测潜在药物分子的有效性，大大加快了药物发现的初始阶段。 Atomwise 在与全球众多制药公司和研究机构建立战略合作伙伴关系方面取得了显著进展，使其技术广泛应用于各个治疗领域。
公司的优势在于其独特的人工智能平台，该平台提供高效的虚拟筛选服务，在候选药物的识别方面取得了很高的成功率。Atomwise 还开展了多项引人注目的合作与并购，巩固了其市场地位，增强了其产品组合和药物研发能力。专注于人工智能和战略扩张，使 Atomwise 在快速发展的药物发现领域保持竞争地位，在全球范围内推动创新和效率。
尽管市场普遍乐观，但必须澄清的是，与某些报道相反，IBM 在 2023 年 8 月并未收购任何 AI 药物研发公司。2022 年，IBM 重组了其早期的医疗保健 AI 项目，并最终成立了 Merative。总体而言，在战略合作伙伴关系、不断发展的平台以及对技术集成的高度重视的推动下，药物研发领域的人工智能技术将持续增长。
What is the projected market valuation for the arket by 2035?
What was the market valuation for the market in 2024?
What is the expected compound annual growth rate (CAGR) for the market from 2025 to 2035?
Which companies are considered key players in the market?
What are the main application segments of the AI in Drug Discovery Market?
The main application segments include Target Identification, Lead Optimization, Drug Repurposing, Clinical Trials, and Preclinical Testing.
How much is the Lead Optimization segment projected to be valued by 2035?
The Lead Optimization segment is projected to be valued at 3.0 USD Billion by 2035.
What technologies are driving the market?
What is the projected valuation for the Machine Learning segment by 2035?
The Machine Learning segment is projected to reach a valuation of 3.8 USD Billion by 2035.
Which end-use sectors are contributing to the AI in Drug Discovery Market?
The end-use sectors contributing to the market include Pharmaceutical Companies, Biotechnology Firms, Research Institutions, and Academic Institutions.
What is the expected valuation for the Assay Development workflow segment by 2035?
The Assay Development workflow segment is expected to be valued at 3.82 USD Billion by 2035.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, clinical trial repositories, and authoritative health technology organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA) Innovation Task Force, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, and Medicines and Healthcare products Regulatory Agency (MHRA) UK. Clinical trial activity was monitored through ClinicalTrials.gov, EU Clinical Trials Register (EudraCT), and WHO International Clinical Trials Registry Platform (ICTRP). Scientific literature was sourced from PubMed/MEDLINE, IEEE Xplore Digital Library, Nature Machine Intelligence, Journal of Chemical Information and Modeling, Cell Systems, and Briefings in Bioinformatics. Patent landscapes were analyzed via USPTO, European Patent Office (EPO), and WIPO databases. Industry and technology standards were reviewed through ISO/IEC JTC 1/SC 42 (Artificial Intelligence), FAIR Data Principles, and IEEE Standards Association. Institutional data was gathered from National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Broad Institute, and Scripps Research. Investment and competitive intelligence was tracked through PitchBook, CB Insights, Crunchbase, and BCIQ (BioCentury Intelligence Quotient). Trade associations including Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Innovation Organization (BIO), European Federation of Pharmaceutical Industries and Associations (EFPIA), and Drug Information Association (DIA) provided regulatory and policy frameworks. These sources were used to collect AI algorithm adoption statistics, regulatory approval pathways for AI-driven drug candidates, clinical pipeline data, partnership and licensing transaction values, and technology landscape analysis across machine learning platforms, deep learning frameworks, natural language processing tools, and knowledge graph technologies.
To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. Supply-side sources included Vice Presidents of Discovery from AI-native drug discovery companies, pharmaceutical AI divisions, biotechnology companies, and computational platform providers, as well as Chief Executive Officers, Chief Technology Officers, Chief Data Officers, Heads of Artificial Intelligence/Machine Learning, and Chief Scientific Officers. Chief medical officers, heads of research and development, directors of global clinical operations, heads of translational medicine, data science leads, and heads of procurement from mid-cap biotechnology companies, academic medical centers, government research institutions, contract research organizations (CROs), and multinational pharmaceutical companies were among the demand-side sources. Primary research collected information on algorithm adoption trends, pharmaceutical partnership structures, licensing fee models, and regulatory submission strategies for AI-enabled drug discovery programs. It also verified AI platform development timelines and validated market segmentation across application areas.
Primary Respondent Breakdown:
• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
• By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)
Global market valuation was derived through revenue mapping and platform deployment analysis. The methodology included:
• Identification of 60+ key technology providers and AI-native drug discovery companies across North America, Europe, Asia-Pacific, and emerging markets
• Product mapping across machine learning, deep learning, natural language processing, knowledge graphs, and robotic process automation categories
• Analysis of reported and modeled annual revenues specific to AI drug discovery software platforms, computational chemistry tools, and predictive analytics suites
• Coverage of technology providers and pharmaceutical AI divisions representing 75-80% of global market share in 2024
• Extrapolation using bottom-up (number of active AI drug discovery programs × average contract value/platform licensing fees by therapeutic area) and top-down (technology provider revenue validation, pharmaceutical R&D AI spend allocation) approaches to derive segment-specific valuations across target identification, lead optimization, drug repurposing, clinical trial optimization, and preclinical testing workflows
请填写以下表格以获取本报告的免费样本
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
